TY - JOUR
T1 - Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment
T2 - Leukemia and Lymphoma
AU - Pennisi, M
AU - Berchicci, L
AU - Miserocchi, E
AU - Mussetti, A
AU - Cacioppo, V
AU - David, A
AU - Scialdone, A
AU - Lorusso, I
AU - Modorati, G
AU - Corradini, P
AU - Montefusco, V
PY - 2019
Y1 - 2019
N2 - Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients’ life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
AB - Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients’ life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
U2 - 10.1080/10428194.2018.1480770
DO - 10.1080/10428194.2018.1480770
M3 - Article
VL - 60
SP - 477
EP - 482
JO - Leuk. Lymphoma
JF - Leuk. Lymphoma
SN - 1042-8194
IS - 2
ER -